Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Holly van Houten
Cardiotoxicity Risk With Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity Matched Study of 1,790 Patients
American Journal of Hematology
Hematology
Related publications
Bortezomib for the Treatment of Multiple Myeloma Patients
Health Technology Assessment
Medicine
Health Policy
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials
Haematologica
Hematology
Update on the Role of Lenalidomide in Patients With Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib
British Journal of Haematology
Hematology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide
European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
